Compared with standard care (SC), are anti-CD19 chimeric antigen receptor (CAR) T cell therapies cost-effective for treating B-cell lymphomas in the second-line or above settings? This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.